UroGen Pharma Reports Second Quarter 2021 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 08/04/21
UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in IsraelBusiness Wire • 07/28/21
UroGen Pharma to Report Second Quarter 2021 Financial Results on Wednesday, August 4, 2021Business Wire • 07/28/21
UroGen Pharma Reports Strong Preliminary Jelmyto® Sales for Second Quarter 2021Business Wire • 07/14/21
UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/13/21
UroGen Pharma Reports First Quarter 2021 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 05/13/21
UroGen Pharma to Report First Quarter 2021 Financial Results on Thursday, May 13, 2021Business Wire • 05/06/21
UroGen Pharma Ltd.'s (URGN) CEO Liz Barrett on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/18/21
UroGen Pharma Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate DevelopmentsBusiness Wire • 03/18/21
UroGen Pharma Announces $75 Million of Non-Dilutive Funding from RTW InvestmentsBusiness Wire • 03/18/21
UroGen Pharma Announces Sponsored Research Agreement with the Johns Hopkins University School of Medicine to Expand Immuno-Oncology PipelineBusiness Wire • 03/15/21
UroGen Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on Thursday, March 18, 2021Business Wire • 03/11/21
UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder CancerBusiness Wire • 01/13/21
URGN Is Worth $50/Share Should It Trade At Revenue Multiples Consistent With Its PeersSeeking Alpha • 01/10/21
UroGen Pharma to Present at the Virtual 39th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/06/21
UroGen Pharma Announces Podium Presentation of Final Jelmyto® Data From Pivotal OLYMPUS Trial at the Annual Meeting of the Society of Urologic OncologyBusiness Wire • 12/03/20
Complete and Durable Responses Observed in OPTIMA II Phase 2b Final Results for UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder CancerBusiness Wire • 11/17/20
Centers for Medicare & Medicaid Services (CMS) Issues Permanent J-Code for UroGen's Jelmyto® Effective January 1, 2021Business Wire • 11/11/20